Clinical Trial Update: A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the long-term safety and tolerability of SEP-363856 in Japanese patients with schizophrenia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SEP-363856

Snippet

Sponsor: Sumitomo Pharma Co., Ltd. | Conditions: Schizophrenia | Phase 3 | Status: TERMINATED